Article Sidebar
Published:
Aug 19, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Clinical significance of peroxiredoxin 2 in esophageal squamous cell carcinoma and its role in cell proliferation and apoptosis in vitro,/i>
Abstract
Purpose: To evaluate the expression of peroxiredoxin 2 (PRDX2) and its clinical significance in esophageal squamous cell carcinoma (ESCC) and its effect on the proliferation and apoptosis of ESCC cells.
Methods: The expression of PRDX2 in clinical tissues (120 samples of tumor tissues compared to 20 samples of non-tumor tissues) was determined. The tissues were divided into high-expression group (n = 56) or low-expression group (n = 64) based on the level of PRDX2. Association between PRDX2 expression and clinicopathological features of patients was further analyzed. In vitro, si-NC and si- PRDX2 were transfected into ECA-109 cells, respectively, to determine the influences of PRDX2 on the function of ESCC cells. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to determine the different expressions of PRDX2 in the clinical tissues.
Results: The results from qRT-PCR indicated that PRDX2 was upregulated in ESCC tissues compared to normal control. Correlation between the expression of PRDX2 and clinical pathological data revealed that the expression of PRDX2 showed correlation with tumor differentiation, size, and clinical tumor node metastasis (TNM) stage. Modulation of PRDX2 expression by transfecting si-PRDX2 in ESCC cell lines demonstrated effective regulation of cell proliferation and apoptosis. Specifically, it was observed that cell proliferation decreased, while cell apoptosis was increased.
Conclusion: Peroxiredoxin 2 is a novel factor that plays a significant role in ESCC progression, and constitutes a potential biomarker and therapeutic target for ESCC.
